Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis

por Landau, H, Smith, M, Landry, C, Chou, J F, Devlin, S M, Hassoun, H, Bello, C, Giralt, S, Comenzo, R L
Publicado 2017

Cancer-testis antigen expression and immunogenicity in AL amyloidosis

por Rosenzweig, M A, Landau, H, Seldin, D, O'Hara, C, Girnius, S, Hanson, N, Frosina, D, Sedrak, C, Arcila, M, Comenzo, R L, Giralt, S, Gnjatic, S, Jungbluth, A A, Koehne, G
Publicado 2012

P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES

por Gertz, M., Cohen, A., Comenzo, R., Kastritis, E., Landau, H., Libby, E., Liedtke, M., Sanchorawala, V., Schönland, S., Wechalekar, A., Ando, Y., Koh, Y., Zonder, J., Palladini, G., Nie, C., Karp, C., Jin, Y., Conrad, A., Kinney, G., Merlini, G.
Publicado 2023

P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS

por Akhlaghi, T., Maclachlan, K., Korde, N., Mailankody, S., Lesokhin, A., Hassoun, H., Lu, S. X., Patel, D., Shah, U., Tan, C., Derkach, A., Lahoud, O., Landau, H. J., Shah, G. L., Scordo, M., Chung, D. J., Giralt, S. A., Usmani, S. Z., Landgren, O., Hultcrantz, M.
Publicado 2022

Fit for Duty: Lessons Learned from Outpatient and Homebound Hematopoietic Cell Transplantation to Prepare Family Caregivers for Home-Based Care

por Applebaum, A.J., Sannes, T., Mitchell, H.R., McAndrew, N.S., Wiener, L., Knight, J.M., Nelson, A.J., Gray, T.F., Fank, P.M., Lahijani, S.C., Pozo-Kaderman, C., Rueda-Lara, M., Miran, D.M., Landau, H., Amonoo, H.L.
Publicado 2023